Learn more about the role
of technology in personalised
breast cancer screening and diagnosis at ECR 2022
The European Commission Initiative on Breast Cancer (ECIBC) guidelines on breast cancer screening and
diagnosis now recommend the use of either digital breast tomosynthesis (DBT) or digital mammography in screening.¹
In addition, the use of DBT is recommended for women with high mammographic breast density detected in previous
screening exams.² Despite being recognised as a risk factor for breast cancer,³ breast density is often still assessed
visually/subjectively by radiologists with high variability in scoring⁴ and there are no aligned breast density assessment and
Identifying women at high risk, such as those with dense breasts, means they can be prioritised
for more frequent or personalised screening, which in turn improves patient outcomes.
Technology has a key role to play in implementing the
ECIBC guidelines and personalised screening
Hologic’s 3D Mammography™ DBT exam has
revolutionised breast cancer detection with better, earlier breast cancer detection for women of all ages and breast densities.
Hologic 3D Mammography finds up to 65% more invasive breast
cancers⁵ and reduces recalls of patients by up to 40%,⁶ compared to 2D mammography alone.
It is the only mammogram approved in
the USA by the FDA as superior to standard 2D mammography for routine breast cancer screening in dense breasts.⁷
Breast imaging technologies that unlock the advantage of time by improving clinical workflow efficiency
3DQuorum™ Imaging Technology utilises Genius AI™ powered analytics to uniquely
reconstruct high-resolution 3D Mammography data to produce 6mm SmartSlices. With no compromise in image quality, sensitivity or
accuracy, 3DQuorum™ speeds up reading time by an hour a day, reducing the number of images to review by
3DQuorum™ also reduces the typical
Hologic high-resolution tomosynthesis and synthesized 2D study size by over 50%, bringing the storage space
and network impact back down to that of standard
resolution 3D™ imaging.⁸
Hologic’s Quantra™ 2.2 software uses a machine-learning algorithm to analyse
breast pattern and texture, providing scores based on ACR BIRADS® Atlas Fifth Edition
By analysing and categorising each patient’s breast texture and pattern,
Quantra™ delivers the accurate information needed to achieve more consistent, more reliable scoring and confidently
design patient-specific screening pathways.
Hologic is proud to be leading the way in advancing AI-powered solutions for
Breast Health which enable earlier and more accurate diagnosis and treatment. Learn more by watching our video.
We look forward to welcoming you to our booth located on the first floor of the ACV in Foyer O, at ECR 2022!
Hologic BV, Da Vincilaan 5, 1930 Zaventem, Belgium
1. European Commission. European Breast Cancer Guidelines:
Digital Breast Tomosynthesis. https://healthcare-quality.jrc.ec.europa.eu/european-breast-cancer-guidelines/screening-tests.
Accessed 30.06.22. 2. European Commission. European Breast Cancer Guidelines: Women with high breast
density. https://healthcare-quality.jrc.ec.europa.eu/european-breast-cancer-guidelines/dense-breast. Accessed 12.2.22.
3. Sprague BL, Gangnon RE, Burt V, et al. Prevalence of mammographically dense breasts in the United States. J Natl Cancer
Inst. 106(10), 2014. 4. Sprague B.L., Conant E.F., Onega T et al, Variation in Mammographic Breast Density Assessments Among
Radiologists in Clinical Practice: A Multicentre Observational Study. Ann Intern Med. Volume 165, Issue 7, Page:457-464 Published at
19 July 2016. 5. Friedewald, SM, et al. “Breast cancer screening using tomosynthesis in combination with digital
mammography.” JAMA 311.24 (2014): 2499-2507. 6. Rafferty E, Park J, Philpotts L, et al., Assessing Radiologist Performance Using
Combined Digital Mammography and Breast Tomosynthesis Compared with Digital Mammography alone: Results of a Multicenter, Multireader
trial. Radiology, 2013 Jan;266(1):104-13 7. Food & Drug Administration Premarket Approval (PMA).
FDA.gov https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P080003S005accessed June 5, 2017. 8. Data on File: TFL-00059. 9. Data on File:
*Based on 8 hours of image interpretation time per
EMB-02028-EUR-EN Rev 001 ©2022 Hologic, Inc. All rights
reserved. Hologic, 3DMammography, 3DQuorum, Genius AI, Quantra, and
associated logos are trademarks or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other
countries. All other trademarks, registered trademarks and product names are the property of their respective owners. This information
is intended for medical professionals and is not intended as a product solicitation or promotion where such activities are prohibited.
Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where
such materials appear. For information on specific products available for sale in a particular country, please contact your Hologic
representative or write to email@example.com
AuntMinnieEurope.com, 671 N Glebe Road, Suite #1610, Arlington, VA 22203 USA